MicroRNAs (miRNAs) have recently emerged as an important new class of cellular regulators that control various cellular processes and are implicated in human diseases, including cancer. Here, we show that loss of let-7 function enhances lung tumor formation in vivo, strongly supporting the hypothesis that let-7 is a tumor suppressor. Moreover, we report that exogenous delivery of let-7 to established tumors in mouse models of non-small-cell lung cancer (NSCLC) significantly reduces the tumor burden. These results demonstrate the therapeutic potential of let-7 in NSCLC and point to miRNA replacement therapy as a promising approach in cancer treatment.
Introduction
MicroRNAs (miRNAs) control various cellular processes such as cell death, differentiation and development, and are implicated in human diseases, including cancer (Esquela-Kerscher and Slack, 2006) . Aberrant expression of specific miRNAs is associated with tumorigenesis and miRNA-coding genes are often found in fragile genomic regions gained and lost in cancers (Calin et al., 2004b; Sevignani et al., 2007) . Many members of one miRNA family in particular, let-7, map to chromosomal regions frequently deleted in lung cancer (Calin et al., 2004b) , and reduced let-7 expression in non-small-cell lung cancer (NSCLC) patients is correlated with poor prognosis (Takamizawa et al., 2004; Yanaihara et al., 2006) . Moreover, let-7 miRNAs are thought to function as tumor suppressors through their negative regulation of multiple oncogenes, such as RAS, MYC and HMGA2, and promoters of cell-cycle progression, such as CDC25A, CDK6 and cyclin-D2 (Johnson et al., , 2007 Lee and Dutta, 2007; Mayr et al., 2007; Park et al., 2007; Sampson et al., 2007; Yu et al., 2007) . Administration of let-7 blocks the growth of cultured lung cancer cells and also prevents the onset of tumor formation in a mouse model of NSCLC (Johnson et al., 2007; Esquela-Kerscher et al., 2008; Kumar et al., 2008) .
Results
In vivo anti-let-7 delivery to lungs leads to increased tumor burden Available data suggest that let-7 miRNA functions as a tumor suppressor that is frequently lost in NSCLC (Takamizawa et al., 2004; Johnson et al., 2005; Yanaihara et al., 2006) , yet no loss-of-function assays have been reported to formally test this hypothesis. The mouse let-7 miRNA family consists of multiple members encoded by 12 genes in the mouse genome, nine of which code for unique mature let-7 molecules and three that code for redundant sequences (Roush and Slack, 2008) . We previously showed that five of the let-7-family members, let-7a, let-7b, let-7c, let-7d and let-7g, consistently reduced the number of proliferating A549 and HepG2 cells by similar levels (Johnson et al., 2007) . As we have not yet detected a difference with any particular let-7-family member, this suggests functional redundancy. Since it is likely that their biological functions overlap, in vivo loss-of-functional genetic tests with the let-7 family are technically difficult. To circumvent this difficulty, we developed a novel protocol to test the role of let-7-family members as tumor suppressors in a well-characterized K-ras autochthonous NSCLC mouse model (Jackson et al., 2001) , LSL-K-ras G12D, containing a recombinasedependent allele of activated Kras with endogenous 5 0 and 3 0 regions. We combined a successful protocol for delivery of small RNAs by intranasal passage (Bitko et al., 2005; Bitko and Barik, 2008) with established in vivo antisense technology (Krutzfeldt et al., 2005) . We designed an anti-miR molecule targeting the let-7g sequence (anti-let-7g) and a control with same GC percentage but no homology in the mouse genome (anti-scrambled (scr)) (see Materials and methods for details). We chose let-7g for this experiment because let-7g maps to 3p21, which has been implicated in the initiation of human lung cancers (Calin et al., 2004a) and also because there is evidence suggesting that let-7gmediated tumor suppression is especially potent in tumors harboring oncogenic K-ras mutations (Kumar et al., 2008) . However, we did not rule out the possibility that our anti-let-7g molecule cross-reacts with other let-7-family members due to their high similarity.
To monitor the delivery of anti-miRs to the lung, we labeled the anti-miR with a fluorescein amidite molecule attached at its 5 0 OH end. We inoculated this labeled anti-miR into mouse lungs by intranasal passage and harvested their lungs 2 h (h) and 16 h later. Both time points showed similar fluorescence signal in the lung ( Supplementary Figure 1) , demonstrating efficient and quick uptake of the modified RNAs. These observations match previously reported data of Bitko et al. (Bitko and Barik, 2008) showing that naked small interfering RNAs can be successfully delivered to the lung via intranasal passage and remain stable.
We transiently delivered the non-labeled anti-miRs to mice carrying a knock-in activated K-ras G12D allele that we had simultaneously inoculated with an adenovirus expressing Cre recombinase (Ad-Cre) to activate LSL-K-ras G12D (Supplementary Figure 2) and initiate lung tumors (as described by Esquela-Kerscher et al., 2008) . In both cases, the lungs show a range of proliferative lesions, including bronchiolar papillary hyperplasia, adenoma, atypical adenomatous hyperplasia and focal low-grade adenocarcinoma. However, mice treated with anti-let-7g (n ¼ 5) displayed more extensive (Po0.01) tumor burden 7 weeks after intranasal inoculation relative to anti-scr control (n ¼ 5), with more prominent bronchiolar papillary hyperplasia ( Figure 1 ). We speculate that transient knockdown of let-7g (and potentially other let-7-family members) function enhances tumorigenicity by elevating the levels of let-7-target genes soon after delivery. This could act synergistically with the K-ras mutation to form a more aggressive NSCLC phenotype similar to the case of the double-mutant mouse model K-ras G12D; Trp-53 flox/flox (Jackson et al., 2005) . This experiment demonstrates a role for let-7 in the suppression of lung tumors via K-ras in vivo and is strong evidence that let-7 functions as a tumor suppressor in the lung.
Intratumoral delivery of let-7 reduces tumor size in a lung cancer xenograft model To study the antitumorigenic role of let-7 in lung cancer, we had previously examined two murine models of human lung cancer, a xenograft model using human lung cancer cells and the LSL-K-ras-G12D model. In the latter mouse model, tumorigenesis was initiated by activation of a gain-of-function K-ras G12D gene through inhalation of Ad-Cre (Jackson et al., 2001) as described above. Using these models, we showed that let-7 suppresses lung tumor initiation, resulting in 66% reduction of tumor burden when comparing K-ras G12D mice treated with let-7 miRNA to those that were treated with control miRNA (Esquela-Kerscher et al., 2008) . Similar findings were made by Jacks' laboratory (Kumar et al., 2008) . Since in both studies let-7 miRNA was delivered at the same time as initiation of tumorigenesis, these two studies showed that let-7 may be useful as preventive therapy against lung cancer in LSL-K-ras G12D mice. While these results revealed an inherent anti-oncogenic activity of let-7 during tumorigenesis, the therapeutic potential of let-7 on established tumors remained unknown.
As most newly diagnosed cases of NSCLC are locally advanced or metastatic at presentation and refractory to most currently applied therapies (Isobe et al., 2005) , we explored the therapeutic potential of let-7 in established tumors. Immunodeficient NOD/SCID mice were subcutaneously inoculated with human H460 lung cancer cells and housed until the tumor cells-initially loosely distributed in matrigel-had formed solid and palpable tumors with an average volume of 100-150 mm 3 . We chose the H460 cell line for this study because it is among the most aggressively growing NSCLC xenografts and is among the cell lines most resistant to other targeted therapies (Siegfried et al., 1999; Hohla et al., 2007) . Beginning on day 11 following inoculation, let-7b or a negative control miRNA (miR-NC) was repeatedly administered by intratumoral injections every 3 days. These synthetic miRNAs were complexed with siPORTamine (siPORT), a lipid-based transfection reagent that enhances cellular uptake of the oligonucleotide. All mice were killed once control animals developed tumors that exceeded an average volume of 600 mm 3 (day 21). As shown in Figure 2a , mice that received miR-NC developed tumors at a pace similar to those treated with siPORT alone or with phosphate-buffered saline (PBS). In contrast, local delivery of synthetic let-7b induced a specific inhibitory response and robustly interfered with tumor growth. Images of tumor-bearing mice on the day of killing are shown in Figure 2b .
Histological analysis revealed that tumors treated with miR-NC or siPORT were densely packed with viable H460 cells and only occasionally contained small necrotic areas (Figure 2c , left panel, center and bottom). These pockets of dead cells are likely due to the aggressive nature of H460 cells that rapidly outgrow other cancer cells and compete for blood supply and nutrients (Edinger and Thompson, 2004) . Tumors that received let-7b, however, contained large areas filled with cell debris (Figure 2c , left panel, top). These tumors also had enlarged necrotic cores, in agreement with the supposition that intratumoral injections preferentially deliver the therapeutic to the center of the tumor. To get better insight into the mechanism of action, we performed immunohistochemical analyses using antibodies specific for Ki-67 and active caspase-3 proteins, markers for cellular proliferation and apoptosis, respectively. As shown in Figure 2c (right panel), H460 cells displayed reduced levels of Ki-67 in response to let-7b treatment. In contrast, active caspase-3 levels remained unaltered. It is possible that let-7 does not specifically induce the apoptotic cascade or alternatively, apoptosis induced by let-7 occurred immediately after administration and is no longer detectable at the time of analysis. This observation is in accordance with our previous observations and indicates a role for let-7 overexpression in interfering with cell-cycle progression rather than a major role in directly inducing programmed cell death (Johnson et al., 2007; Esquela-Kerscher et al., 2008) .
To better correlate therapeutic response with delivery of let-7b, we determined the presence of let-7b oligonucleotides in tumor tissues 24 h after the final administration. Total RNA from H460 tumors treated with let-7b, miR-NC, siPORT or PBS was analyzed by quantitative real-time PCR (qRT-PCR) using let-7bspecific primers. Tumors injected with the let-7b oligo contained B14-fold more let-7b miRNA compared with the endogenous levels present in the controls (Figure 3a ). Since crude tumor tissue was used for this analysis, these levels include extracellular as well as intracellular let-7b. To confirm that synthetic let-7b has successfully been delivered into the cytoplasm of H460 tumor cells and actively engages in the RNA-induced silencing pathway, we evaluated the mRNA levels of NRAS and CDK6, both of which are directly targeted by let-7 miRNA (Esquela-Kerscher et al., 2005; Johnson et al., 2007) . We chose N-ras as a readout for let-7 activity because unlike K-ras mRNA, N-ras mRNA seems to undergo degradation in response to let-7 treatment . As shown in Figure 3b , both transcripts were strongly repressed in tumors that have been injected with let-7b miRNA. Hence, these mRNA levels inversely correlate with increased accumulation of let-7b in these tumors, illustrating successful cellular uptake of the synthetic let-7 mimetic (see Figure 3a ). In addition, downregulation of let-7 targets was confirmed on the protein level by immunohistochemistry directed against proteins for which suitable antibodies were available (Figure 3c ). Similar to reduction of mRNA, tumors treated with let-7b lacked the expression of NRAS protein relative to tumors that received either miR-NC or siPORT. CDC25A protein, another let-7 target that was less responsive on the mRNA level, also showed reduced protein expression in tumors that were injected with let-7b (Johnson et al., 2007) . Thus, synthetic let-7b miRNA successfully entered H460 tumor cells and activated the let-7-silencing pathway to suppress its targets and reduce tumor growth.
Intranasal delivery of let-7 reduces established K-ras-dependent lung tumors To address whether let-7 miRNA can reduce tumor burden in late-stage K-ras G12D animal lungs, 5 Â 10 8 plaque-forming units (PFUs) of Ad-Cre were administered Figure 1 Anti-let-7 enhances tumor formation in activated K-ras lungs. Macroscopic observation of the K-ras G12D mice lungs seven weeks after infection with Ad-Cre. The lung surface of the mice treated with anti-let-7 (a, c) shows higher levels of precancerous lesions in comparison with the lungs treated with anti-scr (b, d) . This observation correlates with a higher load of neoplastic development observed histologically (c, d) . Slides stained by hematoxylin and eosin ( Â 100 amplified) show advanced tumor development in lungs treated with anti-let-7 (e, extended adenoma with acinar and papillar structures) in comparison with the lungs treated with anti-scr (f, earlier neoplastic lesions such as adenomatous and epithelial hyperplasia shown with arrow). (g) Quantification of total tumor area. The ratios of tumor area versus normal lung area are presented as a box-and-whisker plot. Boxes represent interquartile ranges (between the 25th and 75th quartiles) and the two-tailed P-value is indicated. The total range, mean (B)and median (blank bar) are shown. Ad-Cre, adenovirus expressing Cre recombinase; scr, scrambled.
Regression of lung tumors by let-7 P Trang et al intranasally to 6-week-old LSL-Kras-G12D mice and the mice were maintained for 10 weeks. The 10 weeks post-infection group was split into three sets. One set acted as baseline for the study (n ¼ 6) (Figure 4a , bottom, left and center panels). A second set was treated with 1 Â 10 6 infectious units of a lentiviral vector expressing let-7a (lenti-let-7 that showed a three-to four fold upregulation of let-7 miRNA in A549 cells; Supplementary Figure 3 ). The third set was treated with a control empty lentiviral vector (lenti-control). The baseline animals were killed at 10 weeks post Ad-Cre infection. All other animals were incubated further and killed either 2 or 4 weeks post lentiviral infection, and lung morphology, cell proliferation and apoptosis were assessed immunohistochemically. We observed similar lung morphology for both baseline mice and lenticontrol mice that were killed at 2 and 4 weeks post lentiviral infection. Baseline mice and lenti-controls showed bronchiolar papillary hyperplasia and extensive replacement of the parenchyma predominantly by papillary adenocarcinoma (Figure 4a , lower two rows; Figure 4b and Supplementary Figure 4) . In mice administered lenti-let-7, we observed residual bronchiolar papillary hyperplasia, but markedly reduced parenchymal tumor burden when compared with those treated with lenti-control (75% reduction in tumor area) and the baseline animals (64% reduction) (Figure 4a , top; Figure 4b and Supplementary Figure 4) . Also, qRT-PCR analysis revealed that lungs from mice treated with lenti-let-7 contained B5-fold more let-7 oligonucleotides as compared with the controls ( Supplementary  Figure 5a) . These results show that let-7 can effectively cause remission of lung tumors in an advanced K-rasactivated NSCLC mouse model. To evaluate the form of cell death in vivo, we performed TdT-mediated dUTP nick-end labeling (TU-NEL) assays and Ki-67 staining to measure the level of apoptosis and proliferation, respectively. Consistent with the H460 xenograft model, let-7-treated lungs, the control and baseline lungs showed similar levels of TUNEL-positive cells (Supplementary Figure 4b) .
In contrast, let-7-treated lungs lacked Ki-67, suggesting that let-7 overexpression interfered with proliferation of tumor cells in lungs with activated K-ras G12D (Figure 4a, top, right panel) . Therefore, we conclude that let-7 blocks tumor growth by repressing proliferation and eliminating tumor cells potentially through a non-apoptotic mechanism. Apoptosis-unrelated cell death as a means to eliminate cancer cells is a common mechanism of many therapeutic agents and is Regression of lung tumors by let-7 P Trang et al reminiscent of the prevailing form of cell death in solid tumors after cytotoxic therapy (Brown and Wilson, 2003) . let-7 overexpression may lead to cytotoxic-type damage or may disrupt DNA-repair pathways that would correct for naturally occurring damage in the quickly dividing cancer cells.
Discussion
While much work remains to be done to determine the tumor-suppressive mechanism of let-7 in in vivo lung tumors, studies at our laboratory, the Jack's group and by others suggest that let-7 may act through direct repression of the Kras, HMGA2 and c-Myc oncogenes Lee and Dutta, 2007; Sampson et al., 2007; Kumar et al., 2008) . Although Kras might seem to be a critical target in this mouse model, we speculate that other targets are also important, as a recent study showed that sole inhibition of c-Myc resulted in significant inhibition of tumor formation in early stage, and reduction of tumors in late-stage, K-rasactivated lungs (Soucek et al., 2008) .
In conclusion, our studies show that let-7 is a tumor suppressor in lung cancer, and provide proof-of-concept for let-7 replacement therapy as a novel and promising modality to treat lung cancer. Similar to targeted therapies that tackle a gain of function in cancer, such as epidermal growth factor receptor inhibitors, reintroduction of the let-7 tumor-suppressor miRNA interferes with the oncogenic properties of tumor cells and induces a therapeutic response. In contrast to an inhibitory approach, however, 'miRNA replacement therapy' seeks to restore the expression and function of a naturally occurring molecule. Hence, miRNA replacement therapy represents a unique therapeutic opportunity following a different strategy than small-molecule inhibitors, small interfering RNAs and miRNA antagonists, and deserves further exploration. This approach has been successfully demonstrated for liver and metastatic prostate cancer (Kota et al., 2009; Takeshita et al., 2009) . While our results presented here suggest that let-7 miRNAs may prove useful in the treatment of human NSCLC, the challenge for a let-7 therapy will be successful delivery of the miRNA to tumor cells. Local delivery of synthetic let-7 by intratumoral injections resulted in strong inhibition of overall tumor growth. However, this delivery route might be inadequate in a clinical setting as peripheral tumor cells remained present and showed limited knockdown of let-7 targets by immunohistochemistry. Therefore, a delivery technology that facilitates universal access to all tumor cells, such as a systemic delivery route, might be needed to make a let-7 therapeutic more efficacious. Alternatively, adenoviral or retroviral delivery of let-7, as 
Materials and methods

Lung cancer xenografts
Human H460 non-small-cell lung carcinoma cells were cultured in RPMI media (Invitrogen, Carlsbad, CA, USA) following standard tissue culture procedures. H460 cells were trypsinized, counted and subcutaneously injected into the lower back of 6-to 8-week-old NOD/SCID mice (Jackson Laboratories, Bar Harbor, MA, USA) using 3 Â 10 6 cells in 100 ml RPMI with 50% matrigel (BD Biosciences, San Jose, CA, USA) per injection. Once cancer cells have developed palpable tumors, caliper measurements were taken daily and tumor volume was calculated using the formula V ¼ length Â width 2 /2, in which length is greater than width. When tumors reached an average volume of 150 mm 3 , 50 ml synthetic miRNA complexed with the siPORTamine transfection reagent (Ambion, Austin, TX, USA) was delivered intratumorally in 3-day intervals. Synthetic miRNAs are double-stranded and ready-to-use miRNA mimics and were purchased from Ambion, Life Technologies (Austin, TX, USA; pre-miR, cat. no. AM17100). For each injection, 6.25 mg miRNA was complexed with 1.6 ml siPORTamine (Ambion; cat. no. AM4502) reagent in 50 ml PBS. Mice were killed by CO 2 inhalation either 1 or 3 days after the last treatment and tumors were collected and prepared for histology and RNA isolation. All animal experiments were performed under an IACUC-approved animal study protocol.
Quantitative real-time PCR
Total RNA from H460 tumors was isolated using the mirVANA PARIS RNA isolation kit (Ambion) following manufacturer's instructions. For reverse transcription-PCR detection of let-7 mRNA targets in H460 xenografts, 500 ng purified RNA was reverse-transcribed with random decamers using MMLV-RT (cat. no. 28025-021; Invitrogen) with the following incubations: 42 1C for 60 min; 85 1C for 5 min. For reverse transcription-PCR detection of the let-7b oligonucleotide, 10 ng purified RNA was heat-denatured at 70 1C for 2 min and reverse-transcribed using the let-7b TaqMan miRNA Assay (Applied Biosystems, Foster City, CA, USA) with the for 5 min and MMLV-RT (Invitrogen). Gene and let-7b expression levels were determined by real-time PCR using Platinum Taq Polymerase reagents (Invitrogen) using the ABI Prism 7900 SDS (Applied Biosystems). TaqMan Gene Expression Assays (Applied Biosystems) were used with the following cycling conditions: 95 1C for 1 min (initial denature); 50 cycles of 95 1C for 5 s, 60 1C for 30 s. 18S rRNA was amplified as an internal reference to adjust for well-to-well variances in the amount of starting template. The let-7b TaqMan miRNA assay (Applied Biosystems) was used with the following cycling conditions: 95 1C for 1 min (initial denature); 50 cycles of 95 1C for 15 s, 60 1C for 1 min. Total copy numbers of let-7b molecules in tumor tissues were calculated using a standard curve generated with 10 3 -10 12 let-7b copies amplified on the same plate. Quantification of levels of let-7a was performed using the TaqMan miRNA PCR system (ABI, per standard protocol). Levels were normalized to mice treated with Ad-Cre alone (baseline) to determine changes in expression levels 4 weeks post lentiviral infection. 
Anti-scr and anti-let-7 synthesis
The anti-miRs were synthesized by the Keck Facility (Yale University, New Haven, CT, USA). To enhance their stability the anti-miRs were generated using 2 0 -O-methyl-modied nucleotides (italic) and phosphorothioate bonds (*) as follows: anti-let-7g: 5 0 A*C*UGUACAAACUACUACCU*C*A3 0 , anti-scr: 5 0 C*U*CAACAACGUAUAUUCAG*C*A3 0 . The anti-scr RNA was designed using the Scramble RNA software to have the same GC percent as anti-let-7g, but no homology with the mouse genome (Levenkova et al., 2004) . The anti-miR-reporter has a fluorescein amidite attached at the 5 0 of anti-let-7g to follow their delivery using a fluorescence microscope with green fluorescent protein detection wavelengths.
In vivo adenoviral infection and anti-miR delivery to LSL-K-ras G12D mice Approximately 6-week-old LSL-K-ras G12D animals were anesthetized with an isoflurane/propylene glycol mixture and intranasally co-inoculated with adenovirus and anti-miRs (anti-let-7g or scr). The protocol was adapted from Jackson et al. (2001) ; Bitko et al. (2005) ; Bitko and Barik (2008) and Esquela-Kerscher et al. (2008) : 5 Â 10 8 PFUs of Ad-Cre, 60 mg of anti-miR and 0.01M CaCl 2 were mixed in a final volume of 125 ml of Minimal Essential Medium and inoculated to mice in two 62.5-ml instillations as described (Jackson et al., 2001) . Ad-Cre, used to induce tumor formation in LSL-K-ras G12D mice, was purchased from the Gene Transfer Vector Core Facility at the University of Iowa. Mice were killed 7 weeks post infection and the PBS-perfused lungs were retained for analysis. Lungs were prepared for histological analysis to examine tumor burden by fixing the tissue in 4% paraformaldehyde overnight, embedding in paraffin and staining with hematoxylin and eosin. Delivery of anti-miRs in the lung was tested using anti-miR-5 0 fluorescein amidite oligonucleotides using a fluorescence microscope. Ad-Cre recombination was tested using a PCR assay to verify that K-ras G12D mice had undergone Cre-mediated removal of the stop element at the mutant K-ras locus as previously described (Jackson et al., 2001) . Lung and tumor areas were quantified using the ImageJ software in manual measurement mode as described previously (Esquela-Kerscher et al., 2008) . The overall tumor burden was measured as a ratio of total tumor area to total lung area by taking the average of every seventh slide section throughout the lung. Nomenclature based on that of Nikitin et al. (2004) .
Viral constructs and in vivo infection
Ad-Cre was obtained as described previously (Jackson et al., 2001) . Lentivirus expressing let-7a was purchased from Select Biosciences (Mountain View, CA, USA). LSL-K-ras G12D (Jackson et al., 2001 ) (strain number 01XJ6) mice were obtained from the NCI-Frederick Mouse Repository and treated with adenovirus and lentivirus as described previously (Esquela-Kerscher et al., 2008) .
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